Aims: Circulating microRNAs (miRNAs) may represent a novel class of biomarkers; therefore, we examined whether acute myocardial infarction (MI) modulates miRNAs plasma levels in humans and mice.

Methods And Results: Healthy donors (n = 17) and patients (n = 33) with acute ST-segment elevation MI (STEMI) were evaluated. In one cohort (n = 25), the first plasma sample was obtained 517 ± 309 min after the onset of MI symptoms and after coronary reperfusion with percutaneous coronary intervention (PCI); miR-1, -133a, -133b, and -499-5p were ~15- to 140-fold control, whereas miR-122 and -375 were ~87-90% lower than control; 5 days later, miR-1, -133a, -133b, -499-5p, and -375 were back to baseline, whereas miR-122 remained lower than control through Day 30. In additional patients (n = 8; four treated with thrombolysis and four with PCI), miRNAs and troponin I (TnI) were quantified simultaneously starting 156 ± 72 min after the onset of symptoms and at different times thereafter. Peak miR-1, -133a, and -133b expression and TnI level occurred at a similar time, whereas miR-499-5p exhibited a slower time course. In mice, miRNAs plasma levels and TnI were measured 15 min after coronary ligation and at different times thereafter. The behaviour of miR-1, -133a, -133b, and -499-5p was similar to STEMI patients; further, reciprocal changes in the expression levels of these miRNAs were found in cardiac tissue 3-6 h after coronary ligation. In contrast, miR-122 and -375 exhibited minor changes and no significant modulation. In mice with acute hind-limb ischaemia, there was no increase in the plasma level of the above miRNAs.

Conclusion: Acute MI up-regulated miR-1, -133a, -133b, and -499-5p plasma levels, both in humans and mice, whereas miR-122 and -375 were lower than control only in STEMI patients. These miRNAs represent novel biomarkers of cardiac damage.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2980809PMC
http://dx.doi.org/10.1093/eurheartj/ehq167DOI Listing

Publication Analysis

Top Keywords

mir-1 -133a
20
-133a -133b
20
-133b -499-5p
16
plasma levels
12
mir-122 -375
12
lower control
12
circulating micrornas
8
myocardial infarction
8
mirnas represent
8
represent novel
8

Similar Publications

Objectives: Objective of this work was to examine myomiR levels in plasma, skeletal muscle, and skeletal muscle cells of patients with idiopathic inflammatory myopathy (IIM), their interrelations with the disease-related clinical phenotypes and with the effects of the disease-modifying 6-month training-intervention.

Methods: Samples of vastus lateralis muscle (n = 12/13) and plasma (n = 20/21) were obtained from IIM patients and healthy controls, respectively. Muscle and plasma were obtained before and after a 6-month training-intervention in 7 patients.

View Article and Find Full Text PDF

Micro-ribonucleic acids (miRs) are small, non-coding RNAs, which play an important role in atherosclerotic plaque formation, development, and stability. Plaque destabilization and rupture lead to acute coronary syndromes (ACS). Previous studies have implicated several different miRs in the pathogenesis of atherosclerosis.

View Article and Find Full Text PDF

: Available data suggest the diagnostic potential of testing microRNAs (miRs) in myocardial infarction, but their prognostic value remains unclear. To evaluate the prognostic value of circulating miRs (miR-1, miR-21, miR-133a, miR-208 and miR-499) for predicting major adverse cardiac events (MACEs), including death, non-fatal myocardial infarction (MI) or cardiovascular rehospitalization, in patients with non-ST segment elevation acute coronary syndromes (NSTE-ACS). Our prospective, single-center, observational study included patients (pts) with NSTE-ACS admitted <24 h after symptoms onset and pts with confirmed stable coronary artery disease (SCAD) as controls.

View Article and Find Full Text PDF

Identification of reference microRNAs in skeletal muscle of a canine model of Duchenne muscular dystrophy.

Wellcome Open Res

November 2024

Department of Clinical Science and Services, Comparative Neuromuscular Diseases Laboratory, Royal Veterinary College, London, NW1 0TU, UK.

Article Synopsis
  • Duchenne muscular dystrophy (DMD) is a severe condition resulting from mutations in the dystrophin gene, and DE50-MD dogs serve as a model to test new therapies for this disease.
  • * Researchers aimed to find stable microRNA (miR) references for normalizing expression data across different ages and muscle groups in both healthy (WT) and DMD-affected dogs.
  • * The study identified four stable miRs (miR-191, let-7b, miR-125a, and miR-15a) that can be used to accurately normalize the expression levels of other miRs in muscle, indicating differences in miR levels between DE50-MD and WT dogs.
View Article and Find Full Text PDF

MicroRNAs as Biomarkers in Spinal Muscular Atrophy.

Biomedicines

October 2024

Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, SI-1000 Ljubljana, Slovenia.

Spinal muscular atrophy (SMA) is a severe neurodegenerative disease caused by the loss of the survival motor neuron (SMN) protein, leading to degeneration of anterior motor neurons and resulting in progressive muscle weakness and atrophy. Given that SMA has a single, well-defined genetic cause, gene-targeted therapies have been developed, aiming to increase SMN production in SMA patients. The SMN protein is likely involved in the synthesis of microRNAs (miRNAs), and dysregulated miRNA expression is increasingly associated with the pathophysiology of SMA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!